In The News

press releases  |  Key Studies  |  news articles

TB is a global problem and news organizations around the world are chronicling the programs our partners are implementing to improve testing protocols:


JUN 2012

Cepheid Welcomes UNITAID Commitment To Broaden Access To "Ground-Breaking" Xpert MTB/RIF
Cepheid (Nasdaq: CPHD) today welcomed UNITAID's announcement that it has approved funding of $30 million to scale up access to the "ground-breaking" Xpert MTB/RIF in high burden developing countries (HBDC). According to UNITAID, the funds will be used to roll out Xpert-based programs in around 20 countries, in addition to supporting a buy-down of the price of each Xpert MTB/RIF cartridge from $17 currently to around $10.

read full press release

FEB 2011

Cepheid and FIND Announce Collaboration to Develop HIV Viral Load Test
Cepheid (Nasdaq: CPHD) and FIND (Foundation for Innovative New Diagnostics) today announced a new collaboration to accelerate the development of a rapid molecular test for the measurement of human immunodeficiency virus (HIV) viral load.

read full press release

SEP 2010

New England Journal of Medicine Study Reports Xpert MTB/RIF a Faster, More Sensitive & Specific Test for Tuberculosis (TB) Than Current World Standards
Cepheid (Nasdaq: CPHD) today announced that its Xpert® MTB/RIF test was the subject of a study published in the latest edition of the New England Journal of Medicine (NEJM), "Rapid Molecular Detection of Tuberculosis and Rifampin Resistance." The complete study is now available online ( and will appear in the September 9 print edition.

read full press release